GELS
Gelteq Limited Ordinary Shares
There isn't enough reported data to score GELS yet.
GELS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
GELS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
GELS PE Valuation
GELS has no meaningful PE right now: it lost money over the past year.
GELS Forward outlook
There aren't enough analyst estimates for GELS to show an outlook.
GELS Earnings Per Share
GELS Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -1769% | N/A |
| Q4 2024 | -40324% | N/A |
| Q2 2022 | -706% | N/A |
GELS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$251.4K | +$67.1K |
| Q2 2023 | -$318.5K | +$128.3K |
| Q2 2022 | -$446.8K | -$364K |
GELS Net Leverage
GELS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GELS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.9 | Neutral |
| Stochastic | 3.4 | Oversold |
GELS's weekly RSI is 40 (neutral) and its Stochastic is 3 (oversold).
GELS PE vs Healthcare Sector
GELS has no meaningful PE right now: it lost money over the past year.
GELS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.47 | 19% below |
| 20 week MA | $0.56 | 32% below |
| 50 week MA | $0.69 | 45% below |
| 100 week MA | $1.15 | 67% below |
GELS is in a downtrend: it's below all four of its weekly moving averages, and 67% below its 100-week average.
GELS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $2.48 | $2.48 | 0% |
| 2025 | $2.48 | $0.86 | -65% |
| 2026 YTD | $0.86 | $0.38 | -56% |
GELS has finished every year since 2024 lower, and it's down 56% so far in 2026.